Tauopathies – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Tauopathies – Drugs In Development, 2024 report and make more profitable business decisions.
Tauopathies are a group of neurodegenerative disorders characterized by the aggregation of tau protein into neurofibrillary or gliofibrillary tangles in the human brain. Tau protein normally stabilizes microtubules, which are essential for intracellular transport and communication. However, when tau becomes hyperphosphorylated or misfolded, it dissociates from microtubules and forms insoluble aggregates that impair neuronal function and survival. Tauopathies can present with various clinical phenotypes, such as cognitive impairment, behavioral changes, dementia, parkinsonism, and language disorders. Tauopathies can be classified based on the predominant tau isoforms that are present in the inclusions (3R, 4R or equal 3R:4R ratio). Tau biomarkers in cerebrospinal fluid and blood, as well as imaging techniques, can help in the diagnosis and evaluation of tauopathies. Currently, there is no effective treatment for tauopathies, but several tau-targeted therapies are in development.
The Tauopathies drugs in development market research report provide comprehensive information on the therapeutics under development for Tauopathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tauopathies and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Tauopathies | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 51 molecules, with 44 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Tauopathies therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Tauopathies pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Tauopathies treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AC Immune SAADEL Inc
Aeton Therapeutics Inc
Agilvax Inc
Aprinoia Therapeutics Inc
Avrion Therapeutics AG
Axon Neuroscience SE
Beijing Joekai Biotechnology Co Ltd
Biorchestra Co Ltd
Biosplice Therapeutics Inc
Bristol-Myers Squibb Co
Collaborative Medicinal Development LLC
Deutsches Zentrum fur Neurodegenerative Erkrankungen eV
Eikonizo Therapeutics Inc
Eli Lilly and Co
Expansion Therapeutics Inc
Gismo Therapeutics Inc
H. Lundbeck AS
Illimis Therapeutics Inc
Korea Institute of Science and Technology
Mercaptor Discoveries Inc
Modalis Therapeutics Corp
National Institute of Neurological Disorders and Stroke
Neurimmune Holding AG
Neurokine Therapeutics
Neuron23 Inc
New York University
Nido Biosciences Inc
Novartis AG
Novoron Bioscience Inc
Oligomerix inc
Parkure Ltd
Phanes Biotech Inc
Priavoid GmbH
ProMIS Neurosciences Inc
Psy Therapeutics Inc
PTC Therapeutics Inc
Simon Fraser University
Taysha Gene Therapies Inc
Treventis Corp
UCB SA
University of Michigan
University of Oxford
Vaxxinity Inc
WaveBreak Therapeutics
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Tauopathies reports